Quick Answer
Foghorn Therapeutics Inc. reported Operating Income Loss of -$86.39 million for the year ending 2025.
- Foghorn Therapeutics Inc. showed an increase of +15.9% in Operating Income Loss from 2024 to 2025.
- This data is from Foghorn Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Foghorn Therapeutics Inc.'s Operating Income Loss has declined by 69.1%.
- Historical annual values: Fiscal year 2025: -$86.39 million | Fiscal year 2024: -$102.68 million | Fiscal year 2023: -$107.91 million | Fiscal year 2022: -$117.14 million | Fiscal year 2021: -$100.73 million | Fiscal year 2020: -$68.53 million | Fiscal year 2019: -$51.08 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: